Literature DB >> 25606579

The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men ≤ 50 years.

Takeo Kosaka1, Ryuichi Mizuno1, Toshiaki Shinojima1, Akira Miyajima1, Eiji Kikuchi1, Nobuyuki Tanaka1, Kazunobu Shinoda1, Shinya Morita1, Shuji Mikami2, Mototsugu Oya1.   

Abstract

To investigate the appropriate cut-off level of PSA or other clinical parameters at aged ≤ 50 years. The rate of detection of PCa in young men will continue to rise associated with the advancement of the current and evolving practices of screening and detection. In this study, we determined whether to investigate the appropriate cut-off level of PSA or other clinical parameters at aged ≤ 50 years. The study population included 106 patients aged ≤ 50 years who had prostate biopsy at our institute. The differences of clinical variables including various PSA related parameters between the patients with significant PCa and insignificant PCa were analyzed. Receiver operating characteristics (ROC) curves and the corresponding areas under the ROC curves (AUC) were calculated. There were no significant differences between no-PCa and PCa patients regarding PSA value, prostate volume (P vol), PSA density (PSAD), transition zone volume (TZ vol), PSATZ density (PSATZD). When the patients meeting the following criteria, Gleason score was ≤ 6 with less than 2 positive biopsy cores, were classified as having insignificant prostate cancer, PSAD could become a useful predictor of significant PCa in men. The AUC was significantly greater in PSAD (0.801) than for the other parameters. The sensitivity and specificity of a PSAD threshold of 0.32 were 85.7% and 77.8%, respectively. In conclusion, PSAD can be a useful and very effective predictor in a man aged ≤ 50 and we can counsel patients with discretion regarding the likelihood of significant PCa.

Entities:  

Keywords:  PSA density; Prostate cancer; insignificant prostate cancer; prostate biopsy

Year:  2014        PMID: 25606579      PMCID: PMC4297329     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  21 in total

1.  Prospective validation of active surveillance in prostate cancer: the PRIAS study.

Authors:  Roderick C N van den Bergh; Stijn Roemeling; Monique J Roobol; Wouter Roobol; Fritz H Schröder; Chris H Bangma
Journal:  Eur Urol       Date:  2007-05-25       Impact factor: 20.096

2.  Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans.

Authors:  Alice S Whittemore; Piera M Cirillo; David Feldman; Barbara A Cohn
Journal:  J Urol       Date:  2005-09       Impact factor: 7.450

3.  Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer.

Authors:  K Ito; T Yamamoto; Y Kubota; K Suzuki; Y Fukabori; K Kurokawa; H Yamanaka
Journal:  Urology       Date:  2000-08-01       Impact factor: 2.649

4.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

5.  Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.

Authors:  C V Smith; J J Bauer; R R Connelly; T Seay; C Kane; J Foley; J B Thrasher; L Kusuda; J W Moul
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

6.  Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

Authors:  Stacy Loeb; Kimberly A Roehl; Jo Ann V Antenor; William J Catalona; Brian K Suarez; Robert B Nadler
Journal:  Urology       Date:  2006-01-25       Impact factor: 2.649

Review 7.  Active surveillance for prostate cancer: a systematic review of the literature.

Authors:  Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway
Journal:  Eur Urol       Date:  2012-06-07       Impact factor: 20.096

8.  Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003.

Authors:  Masood A Khan; Misop Han; Alan W Partin; Jonathan I Epstein; Patrick C Walsh
Journal:  Urology       Date:  2003-07       Impact factor: 2.649

9.  The patients less than 50 years: is there a need to lower the PSA cutoff point?

Authors:  I A Hekal
Journal:  Prostate Cancer Prostatic Dis       Date:  2008-09-30       Impact factor: 5.554

10.  Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study.

Authors:  Daniel W Lin; Michael Porter; Bruce Montgomery
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

View more
  7 in total

1.  Evaluation of prostate-specific antigen density in the diagnosis of prostate cancer combined with magnetic resonance imaging before biopsy in men aged 70 years and older with elevated PSA.

Authors:  Yoshinori Yanai; Takeo Kosaka; Hiroshi Hongo; Kazuhiro Matsumoto; Toshiaki Shinojima; Eiji Kikuchi; Akira Miyajima; Ryuichi Mizuno; Shuji Mikami; Masahiro Jinzaki; Mototsugu Oya
Journal:  Mol Clin Oncol       Date:  2018-09-19

2.  PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.

Authors:  Sungmin Woo; Sang Youn Kim; Joongyub Lee; Seung Hyup Kim; Jeong Yeon Cho
Journal:  Eur Radiol       Date:  2016-02-04       Impact factor: 5.315

3.  Peripheral zone volume ratio (PZ-ratio) is relevant with biopsy results and can increase the accuracy of current diagnostic modality.

Authors:  Yifan Chang; Rui Chen; Qingsong Yang; Xu Gao; Chuanliang Xu; Jianping Lu; Yinghao Sun
Journal:  Oncotarget       Date:  2017-05-23

4.  Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study.

Authors:  Yin Lei; Tian Jie Li; Peng Gu; Yu Kun Yang; Lei Zhao; Chao Gao; Juan Hu; Xiao Dong Liu
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

5.  PSA density in the diagnosis of prostate cancer in the Chinese population: results from the Chinese Prostate Cancer Consortium.

Authors:  Zi-Jian Song; Jin-Ke Qian; Yue Yang; Han-Xiao Wu; Mao-Yu Wang; Si-Yuan Jiang; Fu-Bo Wang; Wei Zhang; Rui Chen
Journal:  Asian J Androl       Date:  2021 May-Jun       Impact factor: 3.285

6.  A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone.

Authors:  Chaogang Wei; Peng Pan; Tong Chen; Yueyue Zhang; Guangcheng Dai; Jian Tu; Zhen Jiang; Wenlu Zhao; Junkang Shen
Journal:  Transl Androl Urol       Date:  2021-06

7.  Differences in negative predictive value of prostate MRI based in men with suspected or known cancer.

Authors:  Armonde A Baghdanian; Yoon-Jin Kim; Arthur H Baghdanian; Hao N Nguyen; Katsuto Shinohara; Antonio C Westphalen
Journal:  Radiol Bras       Date:  2019 Sep-Oct
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.